Arrowhead Pharmaceuticals vs Novavax
Novavax reported revenue of $1.1 billion in fiscal 2025, 1.4 times Arrowhead Pharmaceuticals' $829 million in fiscal 2025. Arrowhead Pharmaceuticals' revenue grew 23258.2% in its latest year, and Novavax's grew 64.7%. Arrowhead Pharmaceuticals had an operating margin of 11.9%, against 40.3% at Novavax. Free cash flow was $157 million at Arrowhead Pharmaceuticals and −$250 million at Novavax. Their fiscal years end in different months (September 30 and December 31), so the periods don't line up exactly.
Side by side
| Arrowhead Pharmaceuticals | Novavax | |
|---|---|---|
| Latest fiscal year | FY2025, Sep 30, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $829M | $1.1B |
| Revenue growth | 23,258.2% | 64.7% |
| Revenue growth a year, last 5 years | 56.6% | 18.8% |
| Gross margin | — | 93.5% |
| Operating margin | 11.9% | 40.3% |
| Net margin | −0.2% | 39.2% |
| Free cash flow | $157M | −$250M |
| Free cash flow margin | 18.9% | −22.3% |
| Return on capital | — | — |
| Net debt to EBITDA | −5.5x | −1.0x |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 11.7% | 13.7% |
| Last close | $58.16 | $10.78 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $37.3 million | — |
| Piotroski F-score | 5 of 8 | 5 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Arrowhead PharmaceuticalsNovavax
Operating margin
Percent of revenue
Arrowhead PharmaceuticalsNovavax
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Arrowhead PharmaceuticalsNovavax
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Arrowhead Pharmaceuticals and Novavax pages.